Kiniksa licenses vixarelimab to Genentech for $100M upfront; Q2 ARCALYST rev $27M

Kiniksa Pharmaceuticals International, plc

Genentech gets worldwide rights to vixarelimab; Kiniksa receives $100M upfront/near-term and up to $600M in milestones plus tiered royalties.
ARCALYST Q2 2022 net revenue $27.0M (vs. $7.7M Q2 2021); full-year 2022 guidance reaffirmed at $115-130M.
Q2 net loss narrowed to $20.0M (vs. $41.6M), with cash $138.2M and no debt; cash runway into 2025 after deal close.
Phase 2b vixarelimab trial in prurigo nodularis screening complete; data disclosure delayed beyond H2 2022.
Proceeds to fund cardiovascular pipeline expansion; ~20 additional ARCALYST sales reps planned in Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.